Owlet has partnered with healthcare interoperability provider Rhapsody to integrate data from its at-home pulse oximeter, BabySat, directly into the patient’s electronic health records (EHRs).
Owlet’s BabySat is a prescription-only device that continuously monitors a baby’s heart rate and oxygen saturation levels. The device gained US Food and Drug Administration (FDA) clearance in 2023 and is used in infants aged one month and above who have a pre-existing medical condition and require at-home monitoring.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to Owlet, its expansion into clinical settings reflects a growing interest in connected monitoring from healthcare systems nationwide.
Owlet’s president and CEO Jonathan Harris said: “Our partnership with Rhapsody is another step forward in Owlet’s mission to redefine how infant data is integrated and used more effectively within the healthcare system.
“By integrating with the Rhapsody trusted exchange platform, we’ve made sharing infant health data simple, empowering families to make informed decisions and allowing clinicians to deliver better care.”
The completed integration should give clinicians access to real-time insights from the paediatric patients receiving care at home, which Owlet said will make it easier for hospitals to scale up their paediatric remote patient monitoring (RPM) programmes.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataRhapsody’s CEO Sagnik Bhattacharya said: “True interoperability isn’t just about moving data, it’s about making that data meaningful in the moments that matter.
“By connecting Owlet’s clinically validated monitoring data directly into the EHR, we’re giving clinicians a fuller view of their youngest patients, and helping families feel more connected to their child’s care team.”
Other companies are working to bridge the gap between home-based care and clinical oversight. Earlier this month, Pulsenmore gained a de novo classification from the FDA for Pulsenmore ES, an at-home ultrasound platform.
Both Owlet and Pulsenmore’s offerings are part of the telehealth devices and broader patient monitoring markets. Each market is forecast to reach valuations of around $210m and $24.99bn by 2034, respectively, according to GlobalData.
